[go: up one dir, main page]

TR200701870T1 - İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem. - Google Patents

İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.

Info

Publication number
TR200701870T1
TR200701870T1 TR2007/01870T TR200701870T TR200701870T1 TR 200701870 T1 TR200701870 T1 TR 200701870T1 TR 2007/01870 T TR2007/01870 T TR 2007/01870T TR 200701870 T TR200701870 T TR 200701870T TR 200701870 T1 TR200701870 T1 TR 200701870T1
Authority
TR
Turkey
Prior art keywords
crystalline form
imatinib mesylate
preparation
stable crystalline
methyl
Prior art date
Application number
TR2007/01870T
Other languages
English (en)
Inventor
Laxminarayan Pathi Srinivas
Ramchandra Rao Dharmaraj
Narayanrao Kankan Rajendra
Puppala Ravikumar
Original Assignee
Cipla Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited filed Critical Cipla Limited
Publication of TR200701870T1 publication Critical patent/TR200701870T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş, 4-(4-metil piperazın-1-il metil)-N-[4-metıl-3-(4-piridin-3-il) pirimidin-2-il amino) fenil]-benzamidin metan sülfonik asit ilave tuzunun (İmatinib mesilat) kararlı, higroskopik olmayan alfa kristalin formuna ilişkindir. Kristalin formun hazırlanması için işlem de açıklanmıştır.
TR2007/01870T 2004-09-02 2005-09-02 İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem. TR200701870T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN951MU2004 2004-09-02

Publications (1)

Publication Number Publication Date
TR200701870T1 true TR200701870T1 (tr) 2007-05-21

Family

ID=35385539

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2007/01870T TR200701870T1 (tr) 2004-09-02 2005-09-02 İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.

Country Status (4)

Country Link
US (1) US8269003B2 (tr)
KR (1) KR101348625B1 (tr)
TR (1) TR200701870T1 (tr)
WO (1) WO2006024863A1 (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
CN101243066B (zh) * 2005-08-26 2012-11-14 诺瓦提斯公司 甲磺酸伊马替尼的δ和ε晶形
US7893076B2 (en) 2005-11-25 2011-02-22 Novartis Ag Crystalline form F of Imatinib mesylate
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP2311821A1 (en) 2006-04-27 2011-04-20 Sicor, Inc. Polymorphic form of Imatinib mesylate and processes for its preparation
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
WO2009151899A2 (en) * 2008-05-26 2009-12-17 Dr. Reddy's Laboratories Ltd. Preparation of imatinib mesylate
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011100282A2 (en) * 2010-02-09 2011-08-18 Dr. Reddy's Laboratories Ltd. Imatinib mesylate polymorphs
CA2789989A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
EP2547671A1 (en) 2010-03-15 2013-01-23 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
EP2552447A4 (en) * 2010-03-29 2013-09-11 Hetero Research Foundation STABLE PHARMACEUTICAL COMPOSITION OF IMATINIB
US8609842B2 (en) 2010-04-23 2013-12-17 Fujian South Pharmaceutical Co., Ltd. Method for synthesizing Imatinib
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
EP2598499A2 (en) * 2010-07-29 2013-06-05 Dr. Reddy's Laboratories Ltd. Process for the preparation of imatinib mesylate
CN102477031B (zh) 2010-11-30 2015-07-15 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
CN102190649B (zh) * 2011-03-28 2013-01-02 齐鲁天和惠世制药有限公司 一种制备α型甲磺酸伊马替尼的方法
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt
ITMI20111309A1 (it) 2011-07-14 2013-01-15 Italiana Sint Spa Procedimento di preparazione di imatinib mesilato
IN2012DE00728A (tr) 2012-03-13 2015-08-21 Fresenius Kabi Oncology Ltd
CN103467446A (zh) * 2012-06-05 2013-12-25 广东东阳光药业有限公司 一种甲磺酸伊马替尼α晶型的制备方法
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
CN103570674A (zh) * 2012-08-04 2014-02-12 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
US9439903B2 (en) 2012-10-25 2016-09-13 Cadila Healthcare Limited Process for the preparation of amorphous imatinib mesylate
CN103044396A (zh) * 2012-12-14 2013-04-17 浙江华海药业股份有限公司 一种甲磺酸伊马替尼α晶型晶体的制备方法
CN103058991A (zh) * 2012-12-28 2013-04-24 南京艾德凯腾生物医药有限责任公司 一种α晶型甲磺酸伊马替尼的制备方法
US20160122315A1 (en) * 2013-06-12 2016-05-05 Shilpa Medicare Limited Crystalline imatinib mesylate process
EP2927223B1 (en) 2014-04-04 2016-06-29 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing imatinib and salts thereof, free of genotoxic impurity f
WO2015188243A1 (en) * 2014-06-10 2015-12-17 Cristália Produtos Químicos Farmacêuticos Ltda PROCESS FOR PREPARING IMATINIB AND IMATINIB MESYLATE NON-NEEDLE SHAPED α2 FORM
US9902717B2 (en) 2015-03-26 2018-02-27 Unichem Laboratories Limited Process of preparing potassium salt of Azilsartan medoxomil
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (tr) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
TR200504337T1 (tr) * 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
EP1720853B2 (en) * 2004-02-11 2023-06-28 Natco Pharma Limited Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой

Also Published As

Publication number Publication date
KR101348625B1 (ko) 2014-01-07
KR20070063524A (ko) 2007-06-19
US8269003B2 (en) 2012-09-18
WO2006024863A1 (en) 2006-03-09
US20070265288A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
TR200701870T1 (tr) İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
PE20170697A1 (es) Indazoles sustituidos con benzilo como inhibidores de bub1
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1332137T3 (da) Behandling af gastrointestinale stromale tumorer
NO20074287L (no) Pyrazin-2-karboksamidderivater som mGluR5 antagonister
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
CY1109907T1 (el) Διεργασια για την παρασκευη 2-αμινοθειαζολο-5- αρωματικων καρβοξαμιδιων ως αναστολεις κινασων
EA200701245A1 (ru) Производные 2,4(4,6)-пиримидинов
HRP20251220T1 (hr) Derivati bipirazola kao jak inhibitori
PE20091073A1 (es) Derivados de isoxazolo-piridina
TW200637550A (en) Thiazole-4-carboxamide derivatives as mGluR5 antagonists
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
CY1124329T1 (el) N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
MX390378B (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
DE602005023658D1 (de) Verfahren zur herstellung von imatinib-base
PE20070111A1 (es) Aminopirimidinas como moduladores de quinasas
AR057961A1 (es) Derivados de pirrolopirimidinas con actividad inhibitoria de receptor de tirosina quinasa. composiciones farmaceuticas.